Thank you for your post +NeuroInvestment:
I would like to clarify
Pars is a great company. I have much on the Line here x% of PARS.
I Know and have great Faith in MGT Capability.
I am a Long Term INVESTOR
I take issue ONLY with the WORDING and PROCESSof PARS Press Releases and the WAY such PR Releases are Distributed to the terminal of 300,000 Brokers & Traders around the World (DJones/Bridge and Rueter's Terminals).
WORDING
The Wording can be CLEARER and also include QUOTES from INDEPENDENT Opinion Leaders who reviewed the Results and think that Hu211 has a Great potential (Using Quotes from Opinion Leaders about HU211). How many people picked the story on HU211 (it out came one Day Before the Market Reached Bottom Oct 8) ????
There is nothing wrong with informing the people (people that were Too Histerical with Margin Calls to care on OCT 7) that PARS has a good STORY !
PROCESS
The News must be Desimenated in a way that Recognizes the PROCESS by which a SINGLE NEWS Item Reaches the 300,000 ++++ Broker Terminal
These Terminals are the Distribution means of Financial Data to the INVESTMENT COMMUNITY !
These Services are Selcting and Posting One STORY Per Release !!!
For example - Out of today's PR DowJones published only the Financials
Omitted were the Market and Market Share Information for Eye Drugs
and the section on Hu211. IF HU211 IS RECYCLE SO AT LEAST PUT THE MARKET SHARE IN A DIFFERNET RELEASE
Which Tells you that if you have 3 Stories you need 3 Press Releases to tell all 3.
I see that done by companies that issue 3 and 4 press releases per day when they have 3 or 4 stories !!!!!!
This is the Opposite of the PARS PR Release that tells 3 or 4 Stories in one PR RELEASE.
So, I am LONG on this Company and wants to see it succeed and Failed to successfully explain the ABOVE to Management Privately and have them rectify the situation!!
Good Luck to us All
David
Pharmos net loss narrows
ISELIN, N.J., Nov. 3 (Reuters) -
PHARMOS CORPORATION FINANCIAL HIGHLIGHTS
Condensed Consolidated Statement of Operations
For the Three Months Ending
Sept. 30, 1998 Sept. 30, 1997
Revenues
Product Sales $90,743
License Fee $1,663
$92,406 -0-
Cost of goods sold $32,447 -0-
Operating Expenses
R&D, net
(including patent) $731,482 $1,292,631
Selling, general &
administrative $552,466 $528,984
Depreciation &
amortization $64,002 $72,898
Total Operating Expenses $1,347,950 $1,894,513
Other income, net $85,847 $92,016
Net loss before
extraordinary gain ($1,202,144) ($1,802,497)
Extraordinary gain
from forgiveness of debt -0- $416,249
Net Loss ($1,202,144) ($1,386,248)
Preferred dividends &
embedded discount ($62,500) ($714,395)
Net loss attributable
to common shareholders
($1,264,644) ($2,100,643)
Weighted Shares
Outstanding 37,405,455 32,853,545
Net loss per share
applicable to
common shareholders
-- basic and diluted ($0.03) ($0.06)
For the Nine Months Ending
Sept. 30, 1998 Sept. 30, 1997
Revenues
Product Sales $983,899
License Fee $351,663
$1,335,562 -0-
Cost of goods sold $372,299 -0-
Operating Expenses
R&D, net
(including patent) $2,906,266 $4,377,716
Selling, general &
administration $1,712,941 $2,059,948
Depreciation &
amortization $167,717 $215,318
Total Operating Expenses $4,786,924 $6,652,982
Other income, net $287,857 $276,814
Net loss before
extraordinary gain ($3,535,804) ($6,376,168)
Extraordinary gain
from forgiveness of debt -0- $416,249
Net loss ($3,535,804) ($5,959,919)
Preferred dividends &
embedded discount ($874,047) ($2,076,544)
Net loss attributable
to common shareholders ($4,409,851) ($8,036,463)
Weighted Shares
Outstanding 36,621,907 31,852,139
Net loss per share
applicable to
common shareholders
-- basic and diluted ($0.12) ($0.25)
NOTE: The company did not post revenues in Sept. 1997
period. Its products won FDA approval in March, 1998.
More Quotes and News:
Pharmos Corp (Nasdaq:PARS - news)
Related News Categories: health, US Market News |
